AMT initiates preregistration clinical trial for Glybera

Amsterdam Molecular Therapeutics or AMT, a Netherlands-based company engaged in the development of human gene therapy, has initiated treatment of the first patient in a preregistration clinical trial with Glybera. This gene therapy product targets lipoprotein lipase deficiency or LPLD, a seriously debilitating and potentially lethal disease.

The randomized controlled trial has been designed to gather additional data on the effects of Glybera on lipid metabolism and the mechanisms underlying the prevention of pancreatitis attacks. The trial is being performed under a clinical trial application approved by Health Canada.

The new clinical trial builds on positive data obtained from two previous clinical trials in which a total of 22 LPLD patients were treated. These data indicate that a single treatment with Glybera results in a long-term, statistically significant and clinically important reduction in the incidence of acute pancreatitis in LPLD patients, the company said.

The longest follow-up of individual patients is well over three years, and the cumulative follow-up of all patients is more than 45 years. The therapy was well tolerated and no drug-related severe adverse events or unexpected side-effects have been observed, added AMT.

AMT will include the data from the new trial in the marketing authorization application for Glybera. The submission of the dossier to the European Medicines Agency is planned for the second half of 2009.